Barry Coller (Rockefeller University)
Craig Thomas (NCATS)
Jian-kang Jiang (NCATS)
Joshua McCoy (NCATS)
Min Shen (NCATS)
Wenwei Huang (NCATS)
This technology includes methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion, and/or aggregation. The present invention further relates to methods of treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, thrombosis induced by peripheral vascular surgery, peripheral vascular disease or thrombotic disorders resulting from atrial fibrillation or inflammation. Previous work with inhibitors of aIIbP3, particularly 2-ethyl-7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyiimidin-5-one, has shown they are capable of inhibiting fibrinogen binding and platelet aggregation without inducing the binding of one or more integrin P3 LIBS-specific monoclonal antibodies (mAbs). Newly identified inhibitors of aIIbP3 are capable of inhibiting fibrinogen binding and platelet aggregation without inducing the binding of integrin P3 LIBS.
.This invention may offer a therapeutic option within IV bags, EpiPens and as therapy during surgery to avoid adverse clotting events.
Currently available agents are only available in parenteral form and cause adverse reactions (i.e., thrombocytopenia, hypotension).